GlassScriptPhysician profile
Yan Yee Cheng
NPI 1083000640
$2,792.79
in general payments reported to CMS, 2019-2025
19 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $112 · 2023: $129 · 2024: $444 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.01 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.58 | 2022-2025 | |
| Ucb, INC. | $387.03 | 2025 | Rystiggo, Zilbrysq, Nayzilam |
| Acadia Pharmaceuticals INC | $278.05 | 2024-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $259.23 | 2025 | Symbravo, Auvelity |
| Amneal Pharmaceuticals LLC | $253.25 | 2025 | Crexont |
| Janssen Biotech, INC. | $208.55 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $205.52 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $195.86 | 2025 | Rexulti |
| Pfizer INC. | $108.94 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $106.66 | 2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $67.54 | 2025 | |
| Allergan, INC. | $63.55 | 2021 | |
| Argenx US, INC. | $57.42 | 2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $34.06 | 2021 | |
| Neurelis, INC. | $32.22 | 2025 | Valtoco |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $25.23 | 2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $24.15 | 2025 | Xeomin |
| Amgen INC. | $23.42 | 2022 | |
| Lilly USA, LLC | $22.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Yee Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.